#Horizon therapeutics revenue 2020 drivers
#Horizon therapeutics revenue 2020 trial

#Horizon therapeutics revenue 2020 trial

The results from the clinical trial demonstrated that TEPEZZA provides significant improvements in proptosis (eye bulging) and diplopia (double vision) when compared to a placebo.

The New England Journal of Medicine Published TEPEZZA’s Phase 3 Clinical Trial Data: In January 2020, the Company announced that The New England Journal of Medicinehad published the comprehensive results of Phase 3 clinical trial evaluating TEPEZZA for the treatment of TED.

TEPEZZA is the first and only FDA-approved medicine for the treatment of TED, a serious, progressive and vision-threatening rare autoimmune disease. Food and Drug Administration (FDA) approved TEPEZZA (teprotumumab-trbw) for the treatment of TED, well in advance of the Prescription Drug User Fee Act (PDUFA) action date of March 8, 2020.

TEPEZZA Approved by FDA for the Treatment of Thyroid Eye Disease (TED): On Jan.

We remain focused on optimizing the benefits our medicines provide patients and driving value for our shareholders.”įinancial Highlights (in millions except for per share amounts and percentages)įourth-Quarter and Recent Company Highlights net sales expectations to more than $1 billion for each medicine. With the excellent growth potential we see for both TEPEZZA and KRYSTEXXA, we recently increased our peak U.S. We continue to see strong growth for KRYSTEXXA, the only approved medicine for uncontrolled gout, particularly following the significantly higher complete response rate demonstrated when used in combination with methotrexate. “We are in our strongest position ever as a company, entering 2020 with FDA approval of TEPEZZA, the first and only medicine approved for the treatment of thyroid eye disease. “The fourth quarter capped off another year of tremendous progress at Horizon, marked by the achievement of several important milestones,” said Timothy Walbert, chairman, president and chief executive officer, Horizon. 26, 2020- Horizon Therapeutics plc (Nasdaq: HZNP) today announced its fourth-quarter and full-year 2019 financial results and provided its full-year 2020 net sales and adjusted EBITDA guidance. Cash Position of $1.076 Billion Net Leverage of 0.7 Times as of Dec. KRYSTEXXA and TEPEZZA to More Than $1 Billion Each.

#Horizon therapeutics revenue 2020 drivers

Annual Net Sales Expectations for Growth Drivers Strategy to Optimize Treatment Outcomes. Announced KRYSTEXXA Immunomodulation MIRROR Open-Label Trial Top-line Data ħ9 Percent of Patients Achieved a Complete Response, Supporting KRYSTEXXA Immunomodulation TEPEZZA Approved for the Treatment of Thyroid Eye Disease (TED) on Jan.

Launch of TEPEZZA™ and R&D Pipeline Programs to Drive Long-Term Growth. Full-Year 2020 Net Sales Guidance of $1.40 Billion to $1.42 Billion įull-Year 2020 Adjusted EBITDA Guidance of $485 Million to $500 Million, Reflecting Significant Record Full-Year 2019 Net Sales of $1.30 Billion Driven by 32 Percent Growth in KRYSTEXXA® įull-Year 2019 GAAP Net Income of $573.0 Million Record Adjusted EBITDA of $482.8 Million. Record Fourth-Quarter 2019 Net Sales of $363.5 Millionĭriven by 14 Percent Growth in the Orphan and Rheumatology Segment įourth-Quarter 2019 GAAP Net Income of $592.8 Million Adjusted EBITDA of $139.9 Million.